{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:01:20Z","timestamp":1768568480856,"version":"3.49.0"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1111\/jcpt.12393","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T19:19:55Z","timestamp":1463599195000},"page":"306-309","source":"Crossref","is-referenced-by-count":5,"title":["Safety of antitumour necrosis factor treatments in chronic rheumatic diseases: therapy discontinuations related to side effects"],"prefix":"10.1155","volume":"41","author":[{"given":"H.","family":"Varela","sequence":"first","affiliation":[{"name":"Pharmacy; La Paz University Hospital; Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Villama\u00f1\u00e1n","sequence":"additional","affiliation":[{"name":"Pharmacy; La Paz University Hospital; Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Plasencia","sequence":"additional","affiliation":[{"name":"Rheumatology; La Paz University Hospital; Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Romero","sequence":"additional","affiliation":[{"name":"Pharmacy; La Paz University Hospital; Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ruano","sequence":"additional","affiliation":[{"name":"Pharmacy; La Paz University Hospital; Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Balsa","sequence":"additional","affiliation":[{"name":"Rheumatology; La Paz University Hospital; Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Herrero","sequence":"additional","affiliation":[{"name":"Pharmacy; La Paz University Hospital; Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,18]]},"reference":[{"issue":"S3","key":"10.1111\/jcpt.12393-BIB0001|jcpt12393-cit-0001","first-page":"S1","article-title":"Safety of biological therapies: new data from BIOBADASER","volume":"6","author":"Rodr\u00edguez","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1111\/jcpt.12393-BIB0002|jcpt12393-cit-0002","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2217\/imt.13.10","article-title":"Harms of Tumor Necrosis\u00a0Factor Inhibitors in Rheumatic diseases: a focused Systematic Review of the Literature","volume":"5","author":"Jain","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1111\/jcpt.12393-BIB0003|jcpt12393-cit-0003","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12393-BIB0004|jcpt12393-cit-0004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0001-7310(09)70227-3","article-title":"Reactions to infliximab infusions in dermatologic patients: consensus statement and treatment protocol. Working Group of the Grupo Espa\u00f1ol de Psoriasis de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda","volume":"100","author":"Puig","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"10.1111\/jcpt.12393-BIB0005|jcpt12393-cit-0005","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12393-BIB0006|jcpt12393-cit-0006","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12393-BIB0007|jcpt12393-cit-0007","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12393-BIB0008|jcpt12393-cit-0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/rheumatology\/kep325","article-title":"Initiation of rheumatoid arthritis treatments and the risk of serious infections","volume":"49","author":"Grijalva","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/jcpt.12393-BIB0009|jcpt12393-cit-0009","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2011.1692","article-title":"Initiation of tumour necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases","volume":"306","author":"Grijalva","year":"2011","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12393-BIB0010|jcpt12393-cit-0010","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/jcpt.12393-BIB0011|jcpt12393-cit-0011","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ahj.2008.02.025","article-title":"Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis","volume":"156","author":"Setoguchi","year":"2008","journal-title":"Am Heart J"},{"key":"10.1111\/jcpt.12393-BIB0012|jcpt12393-cit-0012","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med"},{"key":"10.1111\/jcpt.12393-BIB0013|jcpt12393-cit-0013","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/jcpt.12393-BIB0014|jcpt12393-cit-0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1699-258X(08)71810-2","article-title":"Adverse Reactions Related to the Administration of TNF Inhibitors. Analysis of a Registry of Biologic Therapy","volume":"4","author":"P\u00e9rez-Zafrilla","year":"2008","journal-title":"Reumatol Clin"},{"key":"10.1111\/jcpt.12393-BIB0015|jcpt12393-cit-0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/acr.20372","article-title":"Safety and efficacy of etanercept beyond 10\u00a0years of therapy in North American patients with early and longstanding rheumatoid arthritis","volume":"63","author":"Weinblatt","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1111\/jcpt.12393-BIB0016|jcpt12393-cit-0016","unstructured":"FDA: Leflunomide Drug Label http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm218691.htm"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12393","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12393\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T12:53:22Z","timestamp":1718542402000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,18]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12393","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5,18]]}}}